GetBriefed Podcast is the latest mdBriefCase Group offering, developed to inform healthcare practitioners regarding a variety of relevant medical topics, and available on a convenient downloadable platform. Now, access education from leading medical experts on-the-go!
GetBriefed Australia Podcast
Claim This Podcastby MDBriefCase
10 episodes
Updated Daily
Accepts GuestsHas SponsorsLocation 🇦🇺
Podcast Overview
GetBriefed Podcast is the latest mdBriefCase Group offering, developed to inform healthcare practitioners regarding a variety of relevant medical topics, and available on a convenient downloadable platform. Now, access education from leading medical experts on-the-go!
Language
🇺🇲
Publishing Since
8/16/2019
1 verified contact email on file for GetBriefed Australia Podcast
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
December 8, 2021
Hepatitis C Stigma - Patient Perspective
<p>Hepatitis C virus (HCV) is a potentially life-threatening virus that primarily affects the liver. While the introduction of direct-acting antiviral therapies which can cure HCV in the majority of patients represents a major advance, stigma represents a key barrier to diagnosis and treatment. As a result, Australia’s Fifth National Hepatitis C Strategy 2018–2022 has identified stigma and discrimination as one of five key priority areas for action.</p> <p>This podcast aims to empower GPs to recognise the different ways in which stigma related to HCV infection can present in the primary care setting and consider communication techniques and tools to help overcome this – thereby optimising outcomes for patient with HCV infection.</p>
November 4, 2020
New CV indication for dulaglutide
<p>Dr Tom Dover explains the new indication for dulaglutide (adjunct to standard of care to reduce the risk of MACE in T2D patients with established CVD OR multiple CVD risk factors) in the context of recent Australian and international guideline recommendations to consider CVD risk when selecting glucose lowering therapies. Practical implications for Australian GPs are discussed.</p>
November 3, 2020
Migraine Matters: CGRP inhibitors – a new era in migraine prevention
<p>This podcast aims to empower GPs to diagnose and adopt best practice management of migraines to improve quality of life and functional outcomes for patients.</p>
10 total episodes available
Deep-dive analytics for GetBriefed Australia Podcast
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is GetBriefed Australia Podcast?
- How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.